[1. Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(2):124–46.10.2174/187221411799015372]Search in Google Scholar
[2. Hermans JF. Les Globuline, Sériques du Système Gamma. Masson et Cie, editor. Paris: Arscia-Bruxelles; 1960.]Search in Google Scholar
[3. Schmid K, Burgi W. Preparation and properties of the human Ba-a2 glycoproteins. Biochim Biophys Acta. 1961;47:440-3.10.1016/0006-3002(61)90539-X]Search in Google Scholar
[4. Pedersen KO. Fetuin, a new globulin isolated from serum. Nature. 1944; 154:575.10.1038/154575a0]Search in Google Scholar
[5. Gejyo, F, Schmid K. Purification and characterization of the two forms of human plasma α2 HS-glycoprotein. Biochim Biophys Acta. 1981; 671(1):78-84.10.1016/0005-2795(81)90096-9]Search in Google Scholar
[6. Kübler D, Gosenca D, Wind M, Heid H, Friedberg I, Jahnen-Dechent W, et al. Proteolytic processing by matrix metalloproteinases and phosphorylation by protein kinase CK2 of fetuin-A, the major globulin of fetal calf serum. Biochimie. 2007;89(3):410-8.10.1016/j.biochi.2006.10.012]Search in Google Scholar
[7. Bendiak B, Harris-Brandts M, Michnick SW, Carver JP, Cumming DA. Separation of the complex asparagine-linked oligosaccharides of the glycoprotein fetuin and elucidation of three triantennary structures having sialic acids linked only to galactose residues. Biochemistry.1989;28(15):6491-9.10.1021/bi00441a050]Search in Google Scholar
[8. Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997; 243(3):753-61.10.1111/j.1432-1033.1997.00753.x]Search in Google Scholar
[9. Haglund AC, Ek B, Ek P. Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo. Biochem J. 2001;357(2):437-45.10.1042/bj3570437]Search in Google Scholar
[10. Hortin GL, Schilling M, Graham JP. Inhibitors of the sulfation of proteins, glycoproteins, and proteoglycans. Biochem Biophys Res Commun.1988;150(1):342-8.10.1016/0006-291X(88)90526-8]Search in Google Scholar
[11. Naseem F, Khan RH, Haq SK, Naeem A. Characterization of molten globule state of fetuin at low pH. Biochim Biophys Acta. 2003;1649(2):16-70.10.1016/S1570-9639(03)00169-9]Search in Google Scholar
[12. Guttman M, Weinkam P,2 Sali A, Lee KK. All-atom ensemble modeling to analyze small-angle x-ray scattering of glycosylated proteins. Structure. 2013; 21(2):321-31.10.1016/j.str.2013.02.004]Search in Google Scholar
[13. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell.1989;58(4):631-40.10.1016/0092-8674(89)90098-6]Search in Google Scholar
[14. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000;164(1-2):87-98.10.1016/S0303-7207(00)00237-9]Search in Google Scholar
[15. Brown WM, Dziegielewska KM, Saunders’ NR, Christie DL, Nawratil P, Muller-Esterl W. The nucleotide and deduced amino acid structures of sheep and pig fetuin. Common structural features of the mammalian fetuin family. Eur J Biochem. 1992;205(1):321-31.10.1111/j.1432-1033.1992.tb16783.x1372866]Search in Google Scholar
[16. Dziegielewska K, Brown WM, Deal, A, Foster KA, Fry EJ, Saunders NR. The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Histochem Cell Biol. 1996;106(3):319-30.10.1007/BF024732428897073]Search in Google Scholar
[17. Carvalho BM, Abdalla Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm. 2013;1-13.10.1155/2013/986734369452723840101]Search in Google Scholar
[18. Cintrón VJ, Ko MS, Chi KD, Gross JP, Srinivas PR, Goustin AS, et al. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res. 2001;1(4):249-63.10.1155/EDR.2000.249247774311467416]Search in Google Scholar
[19. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350(2):437-43.10.1016/j.bbrc.2006.09.07117011519]Search in Google Scholar
[20. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352-9.10.5507/bp.2015.01825916279]Search in Google Scholar
[21. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760-7.10.1161/CIRCULATIONAHA.105.588723277666916567568]Search in Google Scholar
[22. Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012; 61(4):778-9.10.2337/db12-0073331434622442298]Search in Google Scholar
[23. Goustin AS, Derar N,.Abou-Samra AB. Ahsgfetuin blocks the metabolic arm of insulin action through its interaction with the 95-kD β-subunit of the insulin receptor. Cell Signal. 2013;25(4):981-8.10.1016/j.cellsig.2012.12.01123314177]Search in Google Scholar
[24. Goustin A-S. Human Ahsg (fetuin-A) mature protein (model in PyMol) [Internet]. 2012 Jun [cited 2018 Jun 10]. Available from: https://www.youtube.com/watch?v=C212S_owySw]Search in Google Scholar
[25. WHO. Global report on diabetes [Internet]. 2016 [cited 2018 Jun 10]. Available from:http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=B0D9E4564FCBF06628ABAC20F1CC29D6?sequence=1]Search in Google Scholar
[26. Jacobs S, Kröger J, Floegel A, Boeing H, Drogan D, Pischon T, et al. Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPIC-Potsdam Study..Am J Clin Nutr. 2014;100(3):891-900.10.3945/ajcn.113.08031725057154]Search in Google Scholar
[27. Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011;34(1):156-61.10.2337/dc10-0788300544620929991]Search in Google Scholar
[28. Norbert S, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008;57(10):2762-7.10.2337/db08-0538255168718633113]Search in Google Scholar
[29. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin.Endocrinol Metab. 2008;93(11):4479-85.10.1210/jc.2008-150518728159]Search in Google Scholar
[30. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes. 2005;54(8):2477-81.10.2337/diabetes.54.8.247716046317]Search in Google Scholar
[31. Sindhu S, Akhter N, Shenouda S, Wilson A, Ahmad R. Plasma fetuin-A/α2-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes. BMC Immunol. 2016;17:33.10.1186/s12865-016-0171-y503763727671862]Search in Google Scholar
[32. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One. 2011;6(2):e16945.10.1371/journal.pone.0016945303567521347455]Search in Google Scholar
[33. Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY. Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 2018;55(1):87-98.10.1007/s00592-017-1068-929127490]Search in Google Scholar
[34. Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies.. J Endocrinol Invest. 2018;41(1):33-47.10.1007/s40618-017-0697-828643299]Search in Google Scholar
[35. Erdmann J, Salmhofer H, Knauß A, Mayr M, Wagenpfeil S, Sypchenko O, et al. Relationship of fetuin-A levels to weight-dependent insulin resistance and type 2 diabetes mellitus. Regul Pept. 2012;178(1-3):6-10.10.1016/j.regpep.2012.02.00422387701]Search in Google Scholar
[36. Ismail NA, Ragab S, Abd El Dayem SM, ElBaky AA, Salah N, Hamed M, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci. 2012;8(5):826-33.10.5114/aoms.2012.31616350623823185191]Search in Google Scholar
[37. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, et al. Serum fetuin-A is corretaled with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011;216(1):180-6.10.1016/j.atherosclerosis.2011.01.02021310413]Search in Google Scholar
[38. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(19):2533-9.10.1161/CIRCULATIONAHA.106.682450277119617485576]Search in Google Scholar
[39. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765.10.1371/journal.pone.0001765225841618335040]Search in Google Scholar
[40. Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, et al. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 2009;25(5):427-34.10.1002/dmrr.96719405044]Search in Google Scholar
[41. Goustin AS, Abou-Samra AB. The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: insights into the mechanism of insulin resistance. Cell Signalling. 2011;23(6):980-90.10.1016/j.cellsig.2010.11.00321087662]Search in Google Scholar
[42. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010; 95(11):4877-81.10.1210/jc.2010-014820660040]Search in Google Scholar
[43. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, et al. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics. 2007; 6(4):589-600.10.1074/mcp.M600265-MCP20017255083]Search in Google Scholar
[44. Roca-Rivada A, Al-Massadi O, Castelao C, Senín LL, Alonso J, Seoane LM, et al. Muscle tissue as an endocrine organ: comparative secretome profiling of slow-oxidative and fast-glycolytic rat muscle explants and its variation with exercise. JProteomics. 2012;75(17):5414-25.10.1016/j.jprot.2012.06.03722800642]Search in Google Scholar
[45. Perez-Sotelo D, Roca-Rivada A, Larrosa-Garcia M, Castelao C, Baamonde I, Baltar J, et al. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. Endocrine. 2017;55(2):435-46.10.1007/s12020-016-1132-127738888]Search in Google Scholar
[46. Pal D, Dasgupta S, Kundu R, Maitra S, Dias G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279-85.10.1038/nm.285122842477]Search in Google Scholar
[47. Weikert C, Stefan N, Schultze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555-62.10.1161/CIRCULATIONAHA.108.81441819029462]Search in Google Scholar
[48. Laughlin G A, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59(19):1688-96.10.1016/j.jacc.2012.01.038334512722554599]Search in Google Scholar
[49. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf). 2007;66(2):246-50.10.1111/j.1365-2265.2006.02716.x17223995]Search in Google Scholar
[50. Mukhopadhyay S, Mondal SA, Kumar M, Dutta D. Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract. 2014;20(12):1345–51.10.4158/EP14421.RA25370330]Search in Google Scholar
[51. Bilgir O, Kebapcilar L, Bilgir F, Bozkaya G, Yildiz Y, Pinar P, et al. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med. 2010;49(13):1281-5.10.2169/internalmedicine.49.322320606360]Search in Google Scholar
[52. Ix JH, Katz R, de Boer IH, Kestenbaum BR, Peralta CA, Jenny NS, et al. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2012;58(5):887-95.10.1373/clinchem.2011.17772522377528]Search in Google Scholar
[53. Sun ZL, Xie QY, Guo GL, Ma K, Huang YY. Serum fetuin-A levels in patients with cardiovascular disease: a meta-analysis. BioMed Research International. 2014;2014: 691540.10.1155/2014/691540421669125386562]Search in Google Scholar
[54. Laugsand LE, Ix JH, Bartz TM, Djousse L, Kizer JR, Tracy RP, et al. Fetuin-A and risk of coronary heart disease: a Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis. 2015;243(1):44-52.10.1016/j.atherosclerosis.2015.08.031460962126343871]Search in Google Scholar
[55. Sun Q, Jimenez MC, Townsend MK, Rimm EB, Manson JE, Albert CM, et al. Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses’ Health Study. J Am Heart Assoc. 2014;24(3):e000939.10.1161/JAHA.114.000939430909724963103]Search in Google Scholar
[56. Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, et al. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;9:48.10.1186/1475-2840-9-48294971220822519]Search in Google Scholar
[57. Sezer S, Uçar F, Ulusoy EK, Erdogan S, Bilen S, Züngün C, et al. Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers?. Turk J Med Sci. 2014;44(1):16-23.10.3906/sag-1211-9025558553]Search in Google Scholar
[58. Weikert C, Berger K, Heidemann C, Bergmann MM, Hoffmann K, Klipstein-Grobusch K, et al. Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC Potsdam Study. J Neurol. 2007;254(3):315-21.10.1007/s00415-006-0358-x17345050]Search in Google Scholar
[59. Wang YJ, Gong ZQ, Bi XM, Li YL. Correlation of plasma soluble cluster of differentiation 40 ligand, alpha fetoprotein A, and pregnancy-associated plasma protein A with carotid plaque in patients with ischemic stroke. Genet Mol Res. 2015;14(3):8091-9.10.4238/2015.July.17.1826214492]Search in Google Scholar
[60. Jiménez MC, Sun Q, Schürks M, Hu FB, Manson JE, Rexrode KM. Circulating fetuin-A and risk of ischemic stroke in women. Clin Chem. 2014;60(1):165-73.10.1373/clinchem.2013.212597397164424170613]Search in Google Scholar
[61. Wang H, Li W, Zhu S, Li J, D’Amore J, Ward MF, et al. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab. 2010;30(3):493-504.10.1038/jcbfm.2009.247286073819953099]Search in Google Scholar
[62. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HE. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8.10.1210/jc.85.7.2434]Search in Google Scholar
[63. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13.10.2147/CLEP.S37559]Search in Google Scholar
[64. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):671-83.10.1016/j.bpobgyn.2004.05.00115380140]Search in Google Scholar
[65. Dunaif A Insulin resistance and the polycystic ovarysyndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.10.1210/edrv.18.6.0318]Search in Google Scholar
[66. Enli Y, Fenkci SM, Fenkci V, Oztekin O. Serum fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(12):1036-9.10.3109/09513590.2013.82944223961784]Search in Google Scholar
[67. Hasan AL-Aboudy NF, Hussain AL-Ani NK, Reda AlKawaz UM. The effect of different ovarian stimulation protocols on multifunctional fetuin_A concentration in the serum and follicular fluid of women with PCOS undergoing ICSI/IVF. Int. J. of Adv. Res. 2017;5(9):1012-9.10.21474/IJAR01/5418]Search in Google Scholar
[68. Okohue JE, Onuh SO, Ikimalo JI. Comparison of IVF/ICSI outcome in patients with polycystic ovarian syndrome or tubal factor infertility. Niger J Clin Pract. 2013;16(2):207-10.10.4103/1119-3077.11016423563463]Search in Google Scholar
[69. Farhan S, Handisurya A, Todoric J, Tura A, Pacini G, Wagner O, et al. Fetuin-A characteristics during and after pregnancy: result from a case control pilot study. Int J Endocrinol. 2012;896736.10.1155/2012/896736332127922536236]Search in Google Scholar
[70. Kalabay L, Cseh K, Pajor A, Baranyi E, Csákány GM, Melczer Z, et al. Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol. 2002;147(2):243-8.10.1530/eje.0.147024312153747]Search in Google Scholar
[71. Abali R, Celik C, Tasdemir N, Guzel S, Alpsoy S, Yuksel A, et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A concentration and caroid intima-media thickness in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;169(1):45-9.10.1016/j.ejogrb.2013.01.02323433744]Search in Google Scholar
[72. Gulhan I, Bozkaya G, Ozetkin D, Uyar I, Kebapsilar AG, Pamuk B. Serum fetuin-A levels in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;286(6):1473-6.10.1007/s00404-012-2494-022865037]Search in Google Scholar